In the race to find new ways to prevent and treat COVID-19, CCTG has launched an innovative clinical trial focussed on strengthening the immune system for one of the most vulnerable populations – cancer patients.
Tumor DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer (DYNAMIC III)
Nivolumab or Brentuximab Vedotin plus AVD in Pts (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (FINER)
Maintenance Therapy with Olaparib and Cediranib or Olaparib Alone in Relapsed Platinum-sensitive Ovarian Cancer Following a Response to Platinum-Based Chemotherapy
CCTG has announced the commencement of a Phase II study of CFI-400945, an oral, first-in-class inhibitor of Polo-like Kinase 4 in combination with durvalumab, a PD-L1 checkpoint inhibitor, in patients with advanced or metastatic triple negative breast cancer.
Radiation Therapy and Cisplatin Alone or in Combination with Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Pembrolizumab and Brentuximab Vedotin vs GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC)
Perioperative vs Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Archived Bulletins
The Canadian Cancer Trials Group is seeking nominations for the 2021 Recognition Awards honouring individuals who have contributed significantly to the mission and activities of the Group.
The Cancer Research Study Coordinator works within a team based structure to coordinate and oversee national, international and cooperative oncology group, multi-centre, multi-modality clinical trials in cancer therapy, prevention and supportive care.
OlympiA: A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.
The Toronto International Sarcoma Symposium 2021 (virtual format) is just around the corner!
This multidisciplinary symposium will be held on April 09, 2021, and includes speakers and participants from Canada as well as from the International Sarcoma community. The keynote speakers are Dr. Andrew Wagner (Dana Farber) and Dr. David Kirsch (Duke). The one day symposium will feature Clinical and Translational Research among other topics, please see the program page for details.
The CCTG CO29 (AGITG CTDNA-08) - Circulating Tumor DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer: A Multi-centre Phase II/III Randomised Controlled Study (DYNAMIC III) has been centrally activated.
CCTG is hiring and looking for a Manager, Office of Compliance and Oversight (OCO) and a Quality Leader, Office of Clinical Trials Management (OCTM) to join our team at the central operations office at Queen's University.
CCTG is delighted to announce that Dr. Alexander Wyatt has become the new Correlative Sciences Committee Chair for the CCTG GU disease site committee.
Dr. Wyatt is an Assistant Professor in Urologic Sciences at the University of British Columbia, a Senior Research Scientist at the Vancouver Prostate Centre, and Scientist at the BC Cancer Genome Sciences Centre. He has a PhD in genetics (University of Oxford), and now specializes in human genitourinary cancer genomics and bio informatics